The bill, SB 43, establishes the Psychedelic-Assisted Therapy Initiative within the Louisiana Department of Health, specifically within the office of behavioral health. The initiative aims to identify academic health centers conducting clinical studies on psychedelic-assisted therapy for treating opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions. It also seeks to utilize human service districts to identify eligible participants and provide information to parishes using opioid settlement funds to support these studies. Additionally, the initiative will designate a state point of contact to coordinate with federal agencies and other states regarding psychedelic-assisted therapy and related drug development.

The bill includes several amendments, such as expanding the definition of "psychedelic medication," encouraging the use of opioid settlement funds for trial studies, and clarifying revenue attribution from newly developed intellectual property resulting from clinical trials. It authorizes the Department of Health to seek federal funds and requires participating academic health centers to submit annual progress reports. Furthermore, it allows these centers to form consortia with drug developers for conducting clinical trials involving ibogaine and psychedelic medications, ensuring that a portion of revenue from any resulting intellectual property is allocated to the state. The bill is set to take effect on August 1, 2026.